HIF-1/2α-IN-1

Name: HIF-1/2α-IN-1
Brand: TargetMol
SKU: T61442
Rating: 4.5 (1 reviews)

还可以

产品编号 T61442

HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α. Its inhibitory effect on HIF-2α activity is significant, with an IC 50 value of 0.92 μM. Furthermore, HIF-1/2α-IN-1 has the ability to decrease HIF-1α levels. This compound is particularly valuable for research on clear cell renal cell carcinoma (ccRCC) [1].

HIF-1/2α-IN-1

还可以

产品编号 T61442

规格	价格	库存
25 mg	¥ 10,600	10-14周
50 mg	¥ 13,800	10-14周
100 mg	¥ 17,500	10-14周

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

联系我们获取更多批次信息

资源下载

产品操作手册

产品介绍

生物活性

产品描述	HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α. Its inhibitory effect on HIF-2α activity is significant, with an IC 50 value of 0.92 μM. Furthermore, HIF-1/2α-IN-1 has the ability to decrease HIF-1α levels. This compound is particularly valuable for research on clear cell renal cell carcinoma (ccRCC) [1].
体外活性	HIF-1/2α-IN-1 (compound #25) (0.01-100 μM) inhibits HIF-2α activity with an IC 50 value of 0.92 μM [1]. HIF-1/2α-IN-1 (0-10 μM, 24 h) decrease HIF-2α by inhibiting IRE-dependent translation and also inhibit HIF-1α at higher concentrations，which effects mediates by inhibiting the function of iron sulfur cluster assembly 2 (ISCA2) [1]. HIF-1/2α-IN-1 (1 μM, 24 h) targets ISCA2 and trigger the iron starvation response [1]. HIF-1/2α-IN-1 (0-100 μM, 24 h) decreased cell viability in 786-0 cells (IC 50 =1.7 μM (786-0), 10.6 μM (786-0 VHL)) and RCC4 cells (IC 50 =4.8 μM (RCC4), 71.0 μM (RCC4 VHL)) [1]. Cell Viability Assay [1] Cell Line: 786-0 cells and RCC4 cells Concentration: 0.01-100 μM Incubation Time: 24 h Result: Decreased cell viability in 786-0 cells and RCC4 cells. Western Blot Analysis [1] Cell Line: 786-0 cells and RCC10 cells Concentration: 0, 0.5, 1, 2.5, 10 μM Incubation Time: 24 h Result: Decreased HIF-2α activity and protein levels. Decreased HIF-1α levels at higher concentrations or treatment durations, but do not promote proteasomal degradation of HIF-1/2α. Inhibited the production of luciferase driven by the HIF-2α IRE (IRE-Luc). Increasesed IRP2, TFRC in dose-dependent and decreased FTH. RT-PCR [1] Cell Line: 786-0 cells Concentration: 0, 0.5, 1, 5 μM Incubation Time: 24 h Result: Resulted in a dose-dependent decrease in the transcription of HIF-2α target genes VEGFA and POU5F1, but not inhibited HIF-2α transcription.
体内活性	HIF-1/2α-IN-1 (compound #25) (p.o.; 30, 60 mg/kg; daily) significantly reduced ccRCC xenograft growth in vivo [1]. Animal Model: NRG or Balb/c mice [1] (6-8 week old, male, 10 per group) Dosage: 30, 60 mg/kg Administration: p.o., daily Result: Significantly inhibited tumor growth. Had well tolerated with no significant weight loss.